Email this article Fluorescent in situ hybridization: clinical use in oncourology
- Authors: Bashkatov S.V.1, Sevankaev A.V.1, Karyakin O.B.1, Mihaylova G.F.1, Golub Y.V.1
-
Affiliations:
- State Enterprise Medical Radiological Research Center, Russian Academy of Medical Sciences
- Issue: Vol 4, No 3 (2008)
- Pages: 9-15
- Section: LECTURE
- Published: 30.09.2008
- URL: https://oncourology.abvpress.ru/oncur/article/view/1061
- DOI: https://doi.org/10.17650/1726-9776-2008-4-3-9-15
- ID: 1061
Cite item
Full Text
Abstract
Tumor markers for diagnosis of bladder cancer and defining the prognosis of the disease have been actively studied for past decade. FISH-study demonstrates the highest sensitivity and specificity. Abbot Company has developed a diagnostic test system «UroVision» which includes colored DNA-probes referring to 3, 7, 17 and 9p21 chromosomes. This system use provides clinicians with insights into an early diagnosis, prognosis and monitoring of efficacy of anticancer therapy.
About the authors
S. V. Bashkatov
State Enterprise Medical Radiological Research Center, Russian Academy of Medical Sciences
Author for correspondence.
Department of Radiotherapy and Surgery of Urologic Diseases
Obninsk Russian FederationA. V. Sevankaev
State Enterprise Medical Radiological Research Center, Russian Academy of Medical Sciences
Radiation Cytogenetic Laboratory
Obninsk
Russian FederationO. B. Karyakin
State Enterprise Medical Radiological Research Center, Russian Academy of Medical Sciences
Department of Radiotherapy and Surgery of Urologic Diseases
Obninsk Russian FederationG. F. Mihaylova
State Enterprise Medical Radiological Research Center, Russian Academy of Medical Sciences
Radiation Cytogenetic Laboratory
Obninsk
Russian FederationYe. V. Golub
State Enterprise Medical Radiological Research Center, Russian Academy of Medical Sciences
Radiation Cytogenetic Laboratory
Obninsk
Russian FederationReferences
Supplementary files
